Selective serotonin reuptake inhibitors and Alzheimer's disease.
Ontology highlight
ABSTRACT: Given the failure to develop disease-modifying therapies for Alzheimer's disease (AD), strategies aiming at preventing or delaying the onset of the disease are being prioritized. While the debate regarding whether depression is an etiological risk factor or a prodrome of AD rages on, a key determining factor may be the timing of depression onset in older adults. There is increasing evidence that untreated early-onset depression is a risk factor and that late-onset depression may be a catalyst of cognitive decline. Data from animal studies have shown a beneficial impact of selective serotonin reuptake inhibitors on pathophysiological biomarkers of AD including amyloid burden, tau deposits and neurogenesis. In humans, studies focusing on subjects with a prior history of depression also showe
SUBMITTER: Mdawar B
PROVIDER: S-EPMC6862425 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA